GNNSF (GNNSF) Stock Price & Analysis
GNNSF (GNNSF) rose 0.00% to USD 4 as of September 9, 2026 at 22:05 UTC, according to Nexqual real-time market data.
GNNSF last closed at USD 4; the session ranged USD 4.6–4.65 on volume of 1,450 shares. Market capitalization is $8.79B, with a 52-week range of USD 1.3–5 (PNK). Source: Nexqual, September 9, 2026 at 22:05 UTC.
Key Statistics (as of September 9, 2026 at 22:05 UTC)
| Price | USD 4 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 4 |
| Open | USD 4.6 |
| Day Range | USD 4.6 – 4.65 |
| 52-Week Range | USD 1.3 – 5 |
| Volume | 1,450 shares |
| Market Cap | $8.79B |
| Exchange | PNK |
Technical Analysis (GNNSF)
Nexqual's technical model rates GNNSF "STRONG BUY" based on 5 bullish and 0 bearish signals across 126 daily candles, as of September 9, 2026 at 22:05 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.06 (neutral) |
| vs SMA50 | Above (USD 2.67) |
| MACD | 0.49 (positive) |
Analyst Ratings (GNNSF)
Wall Street analysts rate GNNSF "None", per Nexqual as of September 9, 2026 at 22:05 UTC.
| Consensus Rating | None |
|---|
Earnings (GNNSF)
| Next Earnings Date | 2026-08-16 |
|---|
Source: Nexqual, September 9, 2026 at 22:05 UTC.
Financials & Fundamentals (GNNSF)
| Total Revenue | $844.97M |
|---|---|
| Revenue Growth (YoY) | -22.10% |
| Gross Margin | +51.99% |
| Operating Margin | +12.26% |
| Profit Margin | -75.35% |
| ROE | -15.33% |
| Debt / Equity | 8.82 |
| Current Ratio | 1.53 |
| Total Cash | $810.27M |
| Total Debt | $343.53M |
| Free Cash Flow | $52.94M |
Source: Nexqual, September 9, 2026 at 22:05 UTC.
Financial Health Score (GNNSF)
Nexqual rates GNNSF's overall financial health "Solid" across five dimensions, as of September 9, 2026 at 22:05 UTC.
| Growth | Strong — Revenue +61% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 52%, operating 12% |
| Balance Sheet | Strong — $810M cash vs $344M debt, net cash position |
| Cash Flow | Solid — FCF $53M, 6% margin |
| Efficiency | Critical — ROE -15%, ROA 1.5% |
Ownership (GNNSF)
| Insider Ownership | +36.54% |
|---|---|
| Institutional Ownership | +30.39% |
| Shares Outstanding | 2.20B |
| Float | 1.38B |
Source: Nexqual, September 9, 2026 at 22:05 UTC.
Leadership (GNNSF)
GNNSF is led by Weihui Shao (age 45), CEO & COO, per Nexqual as of September 9, 2026 at 22:05 UTC.
| CEO & COO | Weihui Shao (age 45) |
|---|---|
| Executive Chairman | Jiange Meng (age 57) |
| Co-Founder, President & Executive Director | Ye Wang M.S. (age 57) |
| Co-Founder & Executive Director | Fangliang Zhang EMBA (age 60) |
| Chief Strategy Officer & Executive Director | Li Zhu (age 75) |
Major Backers & Investors (GNNSF)
Notable institutional backers of GNNSF include DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT., American Century ETF Trust-Avantis Emerging Markets Equity ETF, Fidelity, according to Nexqual as of September 9, 2026 at 22:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT. | 0.28% |
| American Century ETF Trust-Avantis Emerging Markets Equity ETF | 0.12% |
| Fidelity | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.67% |
| BlackRock | 1.05% |
Source: Nexqual, September 9, 2026 at 22:05 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IVBXF | Innovent Biologics Inc. | USD 13.19 | ▲ 0.57% |
| SBMFF | SINO BIOPHARMACEUTICAL | USD 0.74 | ▲ 0% |
| WXIBF | Wuxi Biologics (Cayman) Inc | USD 6.23 | ▲ 0% |
| UCBJY | UCB S.A. | USD 118.75 | ▼ 2.96% |
| GNMSF | Genmab A/S | USD 329.25 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 22:05 UTC. This page is informational and not investment advice.